» Articles » PMID: 22871503

Identifying Opportunities to Improve Management of Autoimmune Hepatitis: Evaluation of Drug Adherence and Psychosocial Factors

Overview
Journal J Hepatol
Publisher Elsevier
Specialty Gastroenterology
Date 2012 Aug 9
PMID 22871503
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Background & Aims: Recognizing the importance of adherence to therapy in autoimmune hepatitis (AIH) is critical for patient care and avoidance of unnecessary intervention. The influence of psychosocial factors on treatment adherence needs better understanding and prominence. We sought to determine the association between anxiety, depressive symptoms, and avoidant relationship style on self-reported immunosuppressant medication adherence and treatment response in patients with AIH.

Methods: Fifty two patients with AIH were assessed using the Patient Health Questionnaire-9, the Generalized Anxiety Disorder-7, the Experiences in Close Relationship Scale (ECR) and a visual analogue scale to measure self-reported adherence. Laboratory markers of adherence and immunosuppressant treatment response were recorded. Chi-square Fisher's exact or Wilcox rank sum tests were used for comparison between groups.

Results: Treatment responders compared to non-responders were older (p=0.035), had normal or mild score ranges for anxiety and depression (p=0.025) and were significantly more likely to report >80% treatment adherence (p=0.007). Non-responders had higher anxiety symptoms (p=0.025), and significantly higher ECR-avoidance scores (p=0.023), suggestive of a tendency towards a more avoidant relationship style.

Conclusions: We formally document that patients with AIH who have higher depressive and anxiety symptoms and avoidant relationship styles are more likely to be non-adherent to AIH therapy. We reiterate the need for early recognition and treatment of anxiety and depression in patients with AIH, stress the need for treatment adherence and highlight the need for formal evaluation of these factors in trials of therapy targeting apparent treatment non-responders.

Citing Articles

Hellenic Association for the Study of the Liver (HASL): revised clinical practice guidelines for autoimmune hepatitis.

Dalekos G, Papatheodoridis G, Koskinas J, Goulis I, Rigopoulou E, Tiniakos D Ann Gastroenterol. 2024; 37(6):623-654.

PMID: 39568707 PMC: 11574148. DOI: 10.20524/aog.2024.0924.


Depressive symptom as a risk factor for cirrhosis in patients with primary biliary cholangitis: Analysis based on Lasso-logistic regression and decision tree models.

Zhou S, Li J, Liu J, Dong S, Chen N, Ran Y Brain Behav. 2024; 14(8):e3639.

PMID: 39099389 PMC: 11298689. DOI: 10.1002/brb3.3639.


Psychosocial considerations in pediatric autoimmune liver disease.

Wellen B, Lin H, Stellway J Clin Liver Dis (Hoboken). 2022; 20(4):124-129.

PMID: 36245677 PMC: 9549309. DOI: 10.1002/cld.1238.


Confidence in treatment is contributing to quality of life in autoimmune liver diseases. The results of ERN RARE-LIVER online survey.

Wunsch E, Krause L, Gevers T, Schramm C, Janik M, Krawczyk M Liver Int. 2022; 43(2):381-392.

PMID: 36177700 PMC: 10091761. DOI: 10.1111/liv.15440.


Prevalence and biopsychosocial factors associated with treatment adherence among people with epilepsy in a tertiary care hospital in Riyadh, Saudi Arabia.

Almwled A, Almuhaydili A, Altamimi S, Alzahrani M, Alnahdi R, Almotairi S Neurosciences (Riyadh). 2022; 27(2):94-103.

PMID: 35477911 PMC: 9257911. DOI: 10.17712/nsj.2022.2.20210142.